Literature DB >> 24108070

Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors.

Jian Sun1, Dong-Dong Li, Jing-Ran Li, Fei Fang, Qian-Ru Du, Yong Qian, Hai-Liang Zhu.   

Abstract

A series of novel 4-alkoxyquinazoline derivatives were prepared and synthesized and their biological activities were evaluated as potential inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2). Of these compounds, compound 3j demonstrated the most potent inhibitory activities against VEGFR2 tyrosine kinase and cell proliferation, the IC50 values of this compound reaching up to 2.72 nM and 0.35 μM, respectively, compared with Tivozanib (3.40 nM and 0.38 μM). The obtained results, along with a 3D-QSAR study and molecular docking that was used for investigating the probable binding mode, could provide an important basis for further optimization of compound 3j as a potential tyrosine kinase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108070     DOI: 10.1039/c3ob41136b

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  4 in total

Review 1.  Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.

Authors:  Terry-Elinor Reid; Joseph M Fortunak; Anthony Wutoh; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

2.  Synthesis and Anticancer and Antimicrobial Evaluation of Novel Ether-linked Derivatives of Ornidazole.

Authors:  Sevil Şenkardeş; Necla Kulabaş; Özlem Bingöl Özakpinar; Sadık Kalayci; Fikrettin Şahin; İlkay Küçükgüzel; Ş Güniz Küçükgüzel
Journal:  Turk J Pharm Sci       Date:  2020-02-19

3.  Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors.

Authors:  Juan Sun; Xin-Yi Wang; Peng-Cheng Lv; Hai-Liang Zhu
Journal:  Sci Rep       Date:  2015-09-09       Impact factor: 4.379

4.  Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.

Authors:  Yong-Tao Duan; Ruo-Jun Man; Dan-Jie Tang; Yong-Fang Yao; Xiang-Xiang Tao; Chen Yu; Xin-Yi Liang; Jigar A Makawana; Mei-Juan Zou; Zhong-Chang Wang; Hai-Liang Zhu
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.